<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04366492</url>
  </required_header>
  <id_info>
    <org_study_id>HBV-HCV-HIV-001</org_study_id>
    <nct_id>NCT04366492</nct_id>
  </id_info>
  <brief_title>HBV/HCV/HIV in Belgian Prisons</brief_title>
  <official_title>Prevalence of Blood Borne Viral Infections (HBV/HCV/HIV) in the Belgian Prison System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hasselt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Ghent</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hasselt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the prevalence of blood-borne viral infections in prisons in Belgium, screening
      will be executed in several prisons in Flanders, Brussels and Wallonia to obtain a
      geographical representative distribution.

      Upon informed consent screening will be performed using whole capillary blood (finger prick
      testing) with three different tests for HCV Ab, HBsAg and HIV. Screening will be performed
      first. While awaiting the test result (15-20min), the participant can fill out a
      questionnaire (together with the study nurse), concerning risk factors for HCV, HBV and HIV
      infection. This questionnaire is filled out directly online, and will be immediately
      implemented in the encoded database. The database is set-up according to the rules of good
      clinical practice. (Castor EDC software). The results will be filled out immediately by the
      prison staff in this database after it is filled out by the participant, minimizing the risk
      of displacement of test results.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Actual">March 31, 2020</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with HCV Ab+ (Hepatitis C Virus Antibody)</measure>
    <time_frame>day 1</time_frame>
    <description>test using whole capillary blood (finger prick testing)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with HBsAg+ (Hepatitis B surface Antigen)</measure>
    <time_frame>day 1</time_frame>
    <description>test using whole capillary blood (finger prick testing)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with HIV Ab+ (human immunodeficiency virus antibody)</measure>
    <time_frame>day1</time_frame>
    <description>test using whole capillary blood (finger prick testing)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>.Prevalence of blood-borne viral infections in Belgian prisons</measure>
    <time_frame>day 1</time_frame>
    <description>number of HCV Ab+/number of screened prisoners by finger prick
number of HBsAg+/number of screened prisoners by finger prick
number of HIV Ab+/number of screened prisoners by finger prick</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5. Questionnaire to Identify risk factors associated with the aforementioned blood borne viral infections (hepatitis C, hepatitis B and HIV) in prison</measure>
    <time_frame>day 1</time_frame>
    <description>i. Combine results from positive finger prick test with questionnaire regarding sociodemographic factors, migration, risk factors for blood born viruses (sexual contacts, incarceration, drug use)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of uptake counselling by physician in prison</measure>
    <time_frame>day 1</time_frame>
    <description>Percentage of patients with a positive finger prick test who attend a consultation by the prison physician in relation of total tested positive on finger prick</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of uptake of anti(retro)viral treatment</measure>
    <time_frame>day 1</time_frame>
    <description>percentage of positive clients who started treatment in relation of total of positive clients needing treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3045</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Hepatitis B</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>persons in prison</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Prevalence of blood borne viral infections (HBV/HCV/HIV)</intervention_name>
    <description>rapid finger prick test for HCV Ab, HBsAg and HIV and a questionnaire</description>
    <arm_group_label>persons in prison</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥ 18 years

          -  Imprisoned in one of the predefined prisons in Flanders Brussels or Wallonia
             participating in this trial

          -  Written informed consent obtained

        Exclusion Criteria:

          -  Written informed consent not possible: (language barrier, illiteracy)

          -  Already participated in the study: re-entry within inclusion period in one of the
             prisons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geert Robaeys, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hasselt University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dana Busschots, drs.</last_name>
    <role>Study Chair</role>
    <affiliation>Hasselt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hasselt University</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 5, 2020</study_first_submitted>
  <study_first_submitted_qc>April 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2020</study_first_posted>
  <last_update_submitted>April 24, 2020</last_update_submitted>
  <last_update_submitted_qc>April 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hasselt University</investigator_affiliation>
    <investigator_full_name>Geert Robaeys</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

